compound, process for preparing same, pharmaceutical composition, methods for inhibiting dipeptidyl peptidase-iv, for treating conditions mediated by inhibition of dipeptidyl peptidase-iv, increased islet neogenesis, b-cell survival, and insulin biosynthesis in a mammalian patient, and a disease or condition, to treat, control, or prevent diabetes, hyperglycemia, obesity, insulin resistance, one or more disorders, atherosclerosis, one or more conditions in a mammalian patient, neutropenia, and anemia, to treat or control growth hormone deficiency and hiv infection in a mammalian patient, modulate the immune response in a mammalian patient, reduce sperm motility, and produce a pharmaceutical composition, and, pharmaceutical combination

摘要

"COMPOUND, PROCESS TO PREPARE THE SAME, PHARMACEUTICAL COMPOSITION, METHODS TO INHIBIT DIPEPTIDIL PEPTIDASE-IV, TO TREAT CONDITIONS MEASURED BY DIPEPTIDIL PEPTIDASE-IV, INCREASE IN NEOGENES BIOCINES, IN A MAMMALIAN PATIENT, AND A DISEASE OR CONDITION, TO TREAT, CONTROL, OR PREVENT DIABETES, HYPERGLYCEMIA, OBESITY, INSULIN RESISTANCE, ONE OR MORE DISORDERS, ATHEROSCLEROSIS, ONE OR MORE NEPHERIS, ANYPHERIS , TO TREAT OR CONTROL GROWTH HORMENIUM DEFICIENCY AND HIV INFECTION IN A MAMMALIAN PATIENT, TO MODULATE THE IMMUNE RESPONSE IN A MAMMALIAN PATIENT, AND TO REDUCE SPERMATIC MOTIVATION. Dipeptidyl peptidase IV (DPP-IV) inhibitor compounds having formula I are provided: wherein n is 1 or 3; X is CH ~ 2 ~. S; THE; CF ~ 2 ~ or C (CH ~ 3 ~) ~ 2 ~; Z is H; halogen; hydroxyl; C 1-6 alkoxy; C 1-12 alkyl; (C 3-12 cycloalkyl; phenyl; or heteroaryl; wherein the phenyl and heteroaryl groups are optionally mono- or independently multiply substituted by R 7; optionally, X together an adjacent ring carbon and Z form fused cyclopropyl; and optionally one of Ring bonds having X is a double bond, and Cr¬ i¬R¬ ii¬, R¬ 1¬, R¬ 1¬, R¬ 3¬, R¬ 4¬ and R¬ 5¬ are as described herein. Methods for the preparation of these compounds, and methods for the treatment of diabetes, especially Type II diabetes, and other related diseases are described using the compounds of the formula (in pharmaceutical compositions containing these compounds. Pharmaceutical compositions containing combinations These compounds with other antidiabetic agents are also described herein.